Arteriotomy Closure Devices Market Analysis
The Arteriotomy Closure Devices Market size is estimated at USD 1.99 billion in 2025, and is expected to reach USD 2.86 billion by 2030, at a CAGR of 7.54% during the forecast period (2025-2030).
A continued shift toward same-day discharge protocols, the ubiquity of minimally invasive cardiovascular procedures, and strong evidence of reduced hemostasis times are the principal catalysts propelling the arteriotomy closure devices market. Hospitals recognize the operational gains from these solutions, with average time to ambulation dropping from 6.1 hours to 2.8 hours in electrophysiology cases that use closure devices . Large-bore structural heart interventions such as TAVR and EVAR have also accelerated demand, as their arteriotomies can exceed 20F and command premium-priced closure technologies. In parallel, emerging polymer sealants eliminate retained-implant concerns and are helping passive devices gain traction. Finally, robust reimbursement codes in North America and growing procedure volumes in Asia Pacific sustain a healthy pipeline of opportunity for established and new entrants alike.
Key Report Takeaways
- By product type, active closure devices led with 59.08% revenue share in 2024, while passive devices are projected to expand at an 11.71% CAGR through 2030, the fastest among all categories.
- By application, femoral access procedures accounted for 61.63% of the arteriotomy closure devices market share in 2024, whereas large-bore access is advancing at a 9.39% CAGR to 2030.
- By end user, hospitals captured 54.23% of the arteriotomy closure devices market size in 2024, yet ambulatory surgical and catheterization centers show the highest growth at 10.15% CAGR over the forecast horizon.
- By geography, North America maintained 43.32% share of the arteriotomy closure devices market in 2024; Asia Pacific is positioned as the fastest-growing region at an 8.95% CAGR to 2030.
Global Arteriotomy Closure Devices Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Increasing prevalence of cardiovascular & peripheral vascular disorders | +1.8% | Global | Long term (≥ 4 years) |
| Rising geriatric population & PCI volumes | +1.2% | North America & Europe | Medium term (2–4 years) |
| Rapid uptake of transradial & same-day discharge cath-lab programs | +1.5% | Global, early gains in North America | Short term (≤ 2 years) |
| Growth in large-bore interventions (TAVR, EVAR) requiring percutaneous closure | +2.1% | North America & Europe | Medium term (2–4 years) |
| Reimbursement reforms incentivizing outpatient vascular procedures | +1.3% | North America & Europe | Short term (≤ 2 years) |
| Breakthrough bio-absorbable/polymer sealants improving safety profile | +0.9% | Global | Long term (≥ 4 years) |
| Source: | |||
Increasing Prevalence of Cardiovascular & Peripheral Vascular Disorders
Global cardiovascular disease affected 655 million individuals in 2024, and peripheral arterial disease cases have risen 23% since 2010, resulting in sustained growth across diagnostic angiography, PCI, and peripheral interventions that all require reliable closure solutions.[1]JAMA Editors, “Time to Hemostasis Comparative Study,” jamanetwork.com Procedure complexity in diabetic populations often demands repeat access, translating into steady, recurring demand within the arteriotomy closure devices market. Devices cut hemostasis time to around 1 minute versus 10 minutes for manual compression, allowing cath-labs to increase daily caseloads. Precision therapies targeting specific arterial beds likewise necessitate differentiated closure platforms, broadening the product mix that facilities must stock. Consequently, manufacturers that can offer comprehensive portfolios spanning sheath sizes from 5F to 24F are poised to capture incremental revenue.
Rising Geriatric Population & PCI Volumes
Patients older than 75 are the fastest-growing PCI cohort; comorbid calcification and anticoagulation elevate bleeding risk, making device-based closure preferable to manual compression. Outreach data show technical success rates of 94% and major complication rates below 1% when operators deploy closure systems in octogenarian cases.[2]PubMed Central, “Technical Success of Closure Devices in Octogenarians,” pubmed.ncbi.nlm.nih.gov Same-day discharge adds further momentum, particularly since Medicare broadened outpatient PCI reimbursement in 2024. Health-systems also emphasize patient quality-of-life, and quicker ambulation lessens fall risk and hospital-acquired infections. Together these factors reinforce structural, long-term demand drivers for the arteriotomy closure devices market.
Rapid Uptake of Transradial & Same-Day Discharge Cath-Lab Programs
Same-day discharge rates for elective PCI reached 79% in leading cardiac centers by 2024, primarily due to dependable closure technologies that reduce observation times and nurse workload.[3]Journal of the American College of Cardiology, “AMBULATE Trial Findings,” jacc.org Financially, facilities save USD 1,500–2,000 per case, a compelling incentive in value-based care environments. Electrophysiology procedures benefit strongly: the AMBULATE trial documented a 54% cut in time to ambulation and a 58% fall in opioid use when venous closure devices were utilized. COVID-19 constraints further accelerated adoption of outpatient models, prompting permanent infrastructural investments in standalone cath-labs equipped with modern closure tools. Regulatory guidance has now standardized discharge criteria, making same-day protocols routine rather than exception.
Growth in Large-Bore Interventions (TAVR, EVAR) Requiring Percutaneous Closure
TAVR volumes grew 15% year over year through 2024, and sheaths exceeding 20F require robust closure. Specialized devices priced three to four times higher than standard systems have achieved 98% arterial hemostasis with only 0.6% major vascular complications in prospective registries. Closing large arteriotomies eliminates surgical cut-downs, trimming procedure times by up to 34 minutes and supporting patient preference for minimally invasive approaches. As indications expand to intermediate-risk cohorts, the arteriotomy closure devices market gains a premium tailwind.
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High ASPs of active closure devices | -0.8% | Global, emerging markets particularly | Medium term (2–4 years) |
| Device-related complications & steep learning curve | -0.6% | Global | Short term (≤ 2 years) |
| Cost-containment pressures in emerging markets | -0.4% | Asia Pacific, Latin America, MEA | Medium term (2–4 years) |
| Supply-chain dependency on medical-grade collagen & PEG | -0.3% | Global | Long term (≥ 4 years) |
| Source: | |||
High ASPs of Active Closure Devices
Active closure systems range from USD 200 to 400 each, significantly above the USD 50-100 cost of manual compression kits. When large-bore TAVR cases require multiple devices, per-procedure spend can exceed USD 1,000, straining budgets in price-sensitive regions. Although bundled purchasing can offset inpatient days saved, public hospitals in emerging markets often lack capital flexibility, slowing penetration outside tier-one centers.
Device-Related Complications & Steep Learning Curve
Pseudoaneurysm, arterial occlusion, and infection are infrequent yet severe events that demand surgical intervention if closure fails. Data show a pronounced learning curve, with complication rates falling only after operators complete roughly 30 cases. Smaller facilities without sustained volumes may therefore default to manual compression. Manufacturers continue to expand proctor programs and simplify deployment mechanisms, yet operator proficiency remains a gating factor to broader uptake.
Segment Analysis
By Product: Active Devices Maintain Scale; Passive Devices Accelerate
Active platforms accounted for 59.08% of 2024 revenue within the arteriotomy closure devices market, largely on the strength of suture-mediated systems that span 5F-21F sheath sizes and deliver 97.5% technical success in real-world registries. Their immediate hemostasis supports cath-lab throughput, and broad procedural coverage underpins their market leadership.
Passive solutions, however, are set to post an 11.71% CAGR through 2030 as bio-absorbable polymers tackle previous concerns over retained collagen plugs. Early clinical experience indicates 1-minute average hemostasis and rapid resorption inside 30 days, helping passive entries secure incremental share particularly in younger and bariatric populations where foreign-body avoidance is paramount.
By Application: Femoral Dominance Persists; Large-Bore Access Surges
Femoral arterial interventions represented 61.63% of 2024 demand, aligning with entrenched provider familiarity and anatomy that accommodates diverse sheath sizes. Facilities embracing same-day discharge appreciate the 1-2 minute closure times that femoral devices achieve relative to 8-15 minutes via manual compression, lifting daily lab throughput.
Large-bore applications are poised for 9.39% CAGR, mirroring the 15% annual rise in TAVR usage and continued EVAR adoption. Percutaneous closure of 24F arteriotomies eliminates surgical cutdown and shortens case times by up to 34 minutes, presenting high-margin revenue streams for suppliers in the arteriotomy closure devices market.
By End User: Hospitals Lead; Ambulatory Centers Disrupt
Hospitals held 54.23% of 2024 sales thanks to comprehensive trauma management capabilities and close collaboration with device manufacturers for training and adoption. Bundled payments that penalize readmissions further motivate hospitals to prefer devices over manual compression when bleeding risk is elevated.
Ambulatory surgical and catheterization centers should log a 10.15% CAGR. Their dependence on swift ambulation places closure-system performance at the heart of operational economics; devices that reduce observation windows from 6-12 hours to 2-4 hours directly expand daily case capacity and enhance patient satisfaction.
Geography Analysis
North America captured 43.32% of 2024 global revenue in the arteriotomy closure devices market. Medicare and private insurers reimburse closure tools without added patient cost, prompting universal adoption for PCI and electrophysiology procedures. United States operators also cite medico-legal imperatives favoring device-based closure to minimize bleeding complications. Canada’s single-payer model supports closure uptake where cost-utility studies show diminished inpatient days, while Mexico’s growing private hospital sector is upgrading cath-lab capabilities aligned with premium closure technologies.
Europe remains a mature but sizeable arena characterized by stringent evidence requirements and value-oriented purchasing frameworks. Germany leads implantation volumes; the United Kingdom quickly embraces cost-effective plug-based devices; and France and Italy sustain steady growth due to high procedural load and favorable coding for same-day discharge. Post-Brexit regulatory divergence complicates product registration timelines, yet EU MDR certification continues to promote technology differentiation on safety credentials.
Asia Pacific is projected to deliver the fastest regional CAGR of 8.95% to 2030 on the back of expanding cardiac care infrastructure and rising incidence of ischemic heart disease. China’s investment in public and private cath-labs accelerates volume growth, while domestic device players increasingly partner with global leaders for technology transfer. Japan’s advanced reimbursement and procedural sophistication underpin early adoption of bio-absorbable closure platforms. India’s demand outlook remains robust, albeit tempered by acute price sensitivity that requires tiered product offerings and lean distribution.
Competitive Landscape
The arteriotomy closure devices market exhibits moderate consolidation. Abbott, Terumo, and Medtronic collectively held roughly significant share in 2024, leveraging established clinical datasets, expansive sales footprints, and broad portfolios. Abbott’s Perclose family exemplifies first-mover advantage in suture-based closure, while Terumo’s Angio-Seal plug system enjoys entrenched share via decades of safety data and a recent USD 30 million capacity expansion. Medtronic maintains a solid presence with its VenaSeal and ClosureFast ecosystem, complementing arterial offerings.
Competitive pressures are intensifying as mid-tier firms harness material-science advances. Vivasure earned a 2025 CE mark for its fully bio-resorbable PerQseal Elite, signaling potential disruption in large-bore niches. Teleflex paid EUR 760 (USD 893) million for BIOTRONIK’s vascular intervention unit to vertically integrate product pipelines and expand geographically. Future rivalry will likely pivot on bio-absorbability, ease-of-use, and algorithm-guided deployment that reduces operator variability.
Recent Industry Developments
- June 2025: Vivasure Medical Ltd. has received CE mark approval for its PerQseal Elite vascular closure system, a fully bioresorbable, sutureless device designed to manage bleeding in large-bore arterial procedures. Building on this momentum, Vivasure has submitted a Premarket Approval (PMA) application to the U.S. FDA, signaling its intent to enter the U.S. market. Additionally, a newly expanded CE mark covers large-bore venous closures, positioning PerQseal Elite as the first bioresorbable solution in Europe for both arterial and venous vessel access.
- April 2025: HeartBeam, Inc. partnered with AccurKardia to integrate AccurECG, an FDA-cleared ECG analysis software, into HeartBeam’s devices. This collaboration aims to broaden access to remote cardiac monitoring by combining HeartBeam’s hardware innovation with AccurKardia’s software capabilities. Together, they are striving to transform cardiac care delivery beyond traditional medical settings.
- March 2025: Vasorum USA, Inc. secured FDA approval for the Celt ACD PLUS System, an advanced vascular closure device featuring Blood Signal technology. This innovation builds on the proven Celt ACD platform by offering a visual indicator for more precise placement, especially in settings lacking ultrasound imaging enhancing procedural confidence and expanding usability in diverse clinical environments.
- August 2024: Haemonetics Corporation expanded vascular solutions portfolio and announced the full market release of its VASCADE MVP XL mid-bore venous closure system, now available to hospitals across the U.S. This launch strengthens the company's VASCADE portfolio by introducing next-generation features, including a collapsible disc technology and a resorbable collagen patch that promotes rapid hemostasis. Designed to enhance post-procedure outcomes, the MVP XL system offers a sophisticated solution for mid-bore venous access management in interventional settings.